Hydroxyzine Pamoate NDC 51655-252

NDC codes

FDA NDC Directory

Product NDC (as listed)51655-252Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51655-0252Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51655-252-52	51655025252	30 CAPSULE in 1 BOTTLE, PLASTIC (51655-252-52)Marketed from Apr 25, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Hydroxyzine Pamoate
Generic name (nonproprietary): hydroxyzine pamoate
Active ingredients: Hydroxyzine pamoate — 50 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Northwind Health Company, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 088487
Marketing start: Apr 25, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Histamine Receptor Antagonists (Mechanism)
Identifiers: Product ID 51655-252_48e6bda3-48ba-5ce2-e063-6394a90a9e15SPL ID 48e6bda3-48ba-5ce2-e063-6394a90a9e15SPL set ID faf7932b-40ee-8822-e053-6394a90a5e40RxCUI 995278UNII M20215MUFR
Pharmacologic class: Antihistamine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451655025252 followed by a unit qualifier and the quantity

Package 51655-0252-52. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 1, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol ® ) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 088487

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 088487
Product	Strength	Form · route	Labeler	Product NDC
Hydroxyzine Pamoate	Hydroxyzine pamoate 50 mg/1	CapsuleOral	Asclemed USA, Inc.	76420-921
Hydroxyzine Pamoate	Hydroxyzine pamoate 50 mg/1	CapsuleOral	Teva Pharmaceuticals USA, Inc.	0555-0302
Hydroxyzine Pamoate	Hydroxyzine pamoate 50 mg/1	CapsuleOral	American Health Packaging	60687-707